Krasimira Aleksandrova1, Shu-Chun Chuang1, Heiner Boeing1, Hui Zuo1, Grethe S Tell1, Tobias Pischon1, Mazda Jenab1, Bas Bueno-de-Mesquita1, Stein Emil Vollset1, Øivind Midttun1, Per Magne Ueland1, Veronika Fedirko1, Mattias Johansson1, Elisabete Weiderpass1, Gianluca Severi1, Antoine Racine1, Marie-Christine Boutron-Ruault1, Rudolf Kaaks1, Tilman Kühn1, Anne Tjønneland1, Kim Overvad1, J Ramón Quirós1, Paula Jakszyn1, María-José Sánchez1, Miren Dorronsoro1, Maria-Dolores Chirlaque1, Eva Ardanaz1, Kay-Tee Khaw1, Nicholas J Wareham1, Ruth C Travis1, Antonia Trichopoulou1, Pagona Lagiou1, Dimitrios Trichopoulos1, Domenico Palli1, Sabina Sieri1, Rosario Tumino1, Salvatore Panico1, Anne M May1, Richard Palmqvist1, Ingrid Ljuslinder1, So Yeon J Kong1, Heinz Freisling1, Marc J Gunter1, Yunxia Lu1, Amanda J Cross1, Elio Riboli1, Paolo Vineis1. 1. Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrueke, Nuthetal, Germany (KA, HB); Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK (SCC, BBdM, MJG, YL, AJC, ER, PV); Division of Health Policy Translation, Institutes of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan (SCC); Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway (HZ, GST); Molecular Epidemiology Group, Max Delbrueck Center for Molecular Medicine, Berlin-Buch, Germany (TP); International Agency for Research on Cancer, Lyon, France (MJe, SYJK, HF, MJo); National Institute for Public Health and the Environment, Bilthoven, the Netherlands (BBdM); Department of Gastroenterology and Hepatology, University Medical Center, Utrecht, the Netherlands (BBdM); Department of Public Health and Primary Health Care, University of Bergen, Bergen, Norway (SEV); Division of Epidemiology, Norwegian Institute of Public Health, Bergen, Norway (SEV); Bevital AS, Bergen, Norway (ØM); Section for Pharmacology, Department of Clinical Science, University of Bergen, Bergen, Norway (HZ, PMU); Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway (PMU); Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA (VF); Winship Cancer Institute, Emory University, Atlanta, GA (VF); Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway (EW); Department of Research, Cancer Registry of Norway, Oslo, Norway (EW); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (EW); Samfundet Folkhälsan, Helsinki, Finland (EW); Human Genetics Foundation (HuGeF), Torino, Italy (GS, PV); Inserm, Centre for research in Epidemiology and Population Health, U1018, Nutrition, Hormones and Women's Health team, F-94805, Villeju
Abstract
BACKGROUND: Neopterin may be relevant for colorectal cancer (CRC) development, as a biomarker of cellular immune activity exerting pleiotropic effects on cellular ageing, oxidative stress, and inflammation. So far, the association between prediagnostic neopterin and colon and rectal cancer risk has not been evaluated in human populations. METHODS: A nested case-control study was conducted within the European Prospective Investigation into Cancer and Nutrition cohort using data on plasma concentrations of total neopterin (T-N, sum of neopterin and 7,8-dihydroneopterin) in 830 incident CRC case patients (561 colon and 269 rectal) matched within risk sets to 830 control participants. A subsequent replication study used data from the Hordaland Health Study, where 173 CRC case patients have been diagnosed among 6594 healthy participants over 12 years of follow-up. RESULTS: After multivariable adjustment for a priori chosen CRC risk factors, a "U-shaped" association of T-N with CRC was revealed. Compared with the second quintile of the T-N distribution, the relative risks for the first, third, fourth, and fifth quintiles were 2.37 (95% CI = 1.66 to 3.39), 1.24 (95% CI = 0.87 to 1.77), 1.55 (95% CI = 1.08 to 2.22), and 2.31 (95% CI = 1.63 to 3.27), respectively. Replication of these associations within the Hordaland Health Study yielded similar results. No differences have been observed when the associations were explored by colon and rectal cancer site (two-sided P difference = .87) and after excluding case patients diagnosed within the first four follow-up years. CONCLUSIONS: These novel findings provide evidence of the role of both suppressed and activated cell-mediated immunity as reflected by prediagnostic T-N concentrations in the development of CRC.
BACKGROUND: Neopterin may be relevant for colorectal cancer (CRC) development, as a biomarker of cellular immune activity exerting pleiotropic effects on cellular ageing, oxidative stress, and inflammation. So far, the association between prediagnostic neopterin and colon and rectal cancer risk has not been evaluated in human populations. METHODS: A nested case-control study was conducted within the European Prospective Investigation into Cancer and Nutrition cohort using data on plasma concentrations of total neopterin (T-N, sum of neopterin and 7,8-dihydroneopterin) in 830 incident CRC case patients (561 colon and 269 rectal) matched within risk sets to 830 control participants. A subsequent replication study used data from the Hordaland Health Study, where 173 CRC case patients have been diagnosed among 6594 healthy participants over 12 years of follow-up. RESULTS: After multivariable adjustment for a priori chosen CRC risk factors, a "U-shaped" association of T-N with CRC was revealed. Compared with the second quintile of the T-N distribution, the relative risks for the first, third, fourth, and fifth quintiles were 2.37 (95% CI = 1.66 to 3.39), 1.24 (95% CI = 0.87 to 1.77), 1.55 (95% CI = 1.08 to 2.22), and 2.31 (95% CI = 1.63 to 3.27), respectively. Replication of these associations within the Hordaland Health Study yielded similar results. No differences have been observed when the associations were explored by colon and rectal cancer site (two-sided P difference = .87) and after excluding case patients diagnosed within the first four follow-up years. CONCLUSIONS: These novel findings provide evidence of the role of both suppressed and activated cell-mediated immunity as reflected by prediagnostic T-N concentrations in the development of CRC.
Authors: Imrich Blasko; Gabriele Knaus; Elisabeth Weiss; Georg Kemmler; Christiana Winkler; Gerda Falkensammer; Andrea Griesmacher; Reinhard Würzner; Josef Marksteiner; Dietmar Fuchs Journal: J Psychiatr Res Date: 2006-03-20 Impact factor: 4.791
Authors: Monique E Spencer; Alka Jain; Amy Matteini; Brock A Beamer; Nae-Yuh Wang; Sean X Leng; Naresh M Punjabi; Jeremy D Walston; Neal S Fedarko Journal: J Gerontol A Biol Sci Med Sci Date: 2010-05-17 Impact factor: 6.053
Authors: Helga Refsum; Eha Nurk; A David Smith; Per M Ueland; Clara G Gjesdal; Ingvar Bjelland; Aage Tverdal; Grethe S Tell; Ottar Nygård; Stein E Vollset Journal: J Nutr Date: 2006-06 Impact factor: 4.798
Authors: N Slimani; R Kaaks; P Ferrari; C Casagrande; F Clavel-Chapelon; G Lotze; A Kroke; D Trichopoulos; A Trichopoulou; C Lauria; M Bellegotti; M C Ocké; P H M Peeters; D Engeset; E Lund; A Agudo; N Larrañaga; I Mattisson; C Andren; I Johansson; G Davey; A A Welch; K Overvad; A Tjønneland; W A Van Staveren; R Saracci; E Riboli Journal: Public Health Nutr Date: 2002-12 Impact factor: 4.022
Authors: Mazda Jenab; Elio Riboli; Rebecca J Cleveland; Teresa Norat; Sabina Rinaldi; Alexandra Nieters; Carine Biessy; Ann Tjønneland; Anja Olsen; Kim Overvad; Henning Grønbaek; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Jakob Linseisen; Heiner Boeing; Tobias Pischon; Dimitrios Trichopoulos; Eleni Oikonomou; Antonia Trichopoulou; Salvatore Panico; Paolo Vineis; Franco Berrino; Rosario Tumino; Giovanna Masala; Petra H Peters; Carla H van Gils; H Bas Bueno-de-Mesquita; Marga C Ocké; Eiliv Lund; Michelle A Mendez; María José Tormo; Aurelio Barricarte; Carmen Martínez-García; Miren Dorronsoro; José Ramón Quirós; Göran Hallmans; Richard Palmqvist; Göran Berglund; Jonas Manjer; Timothy Key; Naomi E Allen; Sheila Bingham; Kay-Tee Khaw; Anne Cust; Rudolf Kaaks Journal: Int J Cancer Date: 2007-07-15 Impact factor: 7.396
Authors: C Huber; J R Batchelor; D Fuchs; A Hausen; A Lang; D Niederwieser; G Reibnegger; P Swetly; J Troppmair; H Wachter Journal: J Exp Med Date: 1984-07-01 Impact factor: 14.307
Authors: Tonje S Steigedal; Jimita Toraskar; Richard P Redvers; Marit Valla; Synnøve N Magnussen; Anna M Bofin; Signe Opdahl; Steinar Lundgren; Bedrich L Eckhardt; John M Lamar; Judy Doherty; Richard O Hynes; Robin L Anderson; Gunbjørg Svineng Journal: Neoplasia Date: 2018-03-11 Impact factor: 5.715
Authors: Maria L Wikberg; Robin Myte; Richard Palmqvist; Bethany van Guelpen; Ingrid Ljuslinder Journal: Cancer Med Date: 2018-03-23 Impact factor: 4.452